TOP STORIES

Health reform survives

In a complex decision, a slim majority of the Supreme Court upheld the constitutionality of the Affordable Care Act. » More

FDA approves first weight-loss treatment in over a decade

FDA has approved lorcaserin (Belviq, Arena Pharmaceuticals and Eisai) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who are overweight or obese and have at least 1 weight-related comorbid condition. It is the first prescription weight-loss treatment approved by FDA in 13 years. » More

CONTINUING EDUCATION

Psychopharmacology for the elderly

Late-life depression can occur in up to 50% of patients. Pharmacists can screen for unidentified cases and advocate for routine measurement of symptom severity.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.

EDITOR’S PICK

Management of chronic kidney disease: An emphasis on delaying disease progression and treatment options

Chronic kidney disease, also known as chronic renal disease, is characterized by a progressive deterioration in renal function ultimately leading to irreversible loss of nephrons and nephron function. This decline can occur over several months or can take years to progress. » Click here.

CLINICAL NEWS

Humana, Novo Nordisk partner for diabetes care

Humana Inc. and Novo Nordisk have announced a 1-year partnership aimed at identifying ways to improve the care and treatment of patients with diabetes. » More

Dabigatran prescribing information is updated

Label prescribing information for dabigatran (Pradaxa, Boehringer Ingelheim) capsules has been updated to affirm that the 150-mg twice-daily dose is superior to warfarin in reducing ischemic and hemorrhagic strokes in patients with nonvalvular atrial fibrillation. » More

Survey

Based upon your experience with Medication Therapy Management (MTM) programs and services to date, how would you assess their impact in improving healthcare quality and lowering healthcare costs in their targeted patient population?

a) Highly effective
b) Somewhat effective
c) Neutral
d) Somewhat ineffective
e) Largely ineffective

Click here and see what your colleagues think, too.

Want to see the results of our last survey about specialty pharmacy services? Click here.

Confirm your
e-newsletter subscription click here.

To ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff

Resources

Digital Edition